Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Experts are casting a wide net for treatments, with few ready for formal clinical trials.
Get a COVID booster, especially if you’re older or your immune system is compromised, and don’t forget the flu shot.
Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?
The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.
The monoclonal antibody combo is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
Higher levels of viral antigens in the blood correlated with more severe disease.
The update aims to help the public better protect themselves and understand their risk.
People of European or African ancestry who were hospitalized for COVID-19 are more likely to carry particular genetic variants.
Two drugs widely used to treat certain autoimmune diseases substantially improved clinical status and reduced deaths.
Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition.
With further testing, the antiviral proteins might be used as a nasal spray to prevent or treat COVID-19.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
The United States might see one of the steepest increases in the country’s uninsured rate in years.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
The CDC’s move triggered mixed feelings from the public and laid bare a split within the health care community.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.